Results 111 to 120 of about 357,928 (304)

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Preserved auditory-motor synchronization during finger-tapping to music and metronomes at various tempi in progressive multiple sclerosis

Frontiers in Neurology
BackgroundPersons with relapsing and remitting multiple sclerosis (MS) can synchronize steps with music and metronomes at different tempi. However, progressing demyelination, loss of neural connectivity and increased cognitive impairment likely affects ...
Nele Vanbilsen, Nele Vanbilsen, Peter Feys, Peter Feys, Mattia Rosso, Bart Van Wijmeersch, Bart Van Wijmeersch, Daphne Kos, Daphne Kos, Marc Leman, Sonja A. Kotz, Lousin Moumdjian, Lousin Moumdjian, Lousin Moumdjian   +13 more
doaj   +1 more source

Adaptive clinical trials incorporating treatment selection and evaluation: methodology and application in progressive multiple sclerosis [PDF]

, 2009
In progressive multiple sclerosis (MS) irreversible disability often takes many years to accumulate as a result prolonged trials are required to assess the benefits of therapies.
Chataway, Jeremy, Friede, Tim, Nicholas, R. (Richard), Parsons, Nicholas R., Stallard, Nigel, Todd, S. C. (Susan C.), Valdés-Márquez, Elsa   +6 more
core  

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

Frontiers in Immunology
IntroductionAnti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and ...
Regina Berkovich, Jonathan Calkwood, Heidi Crayton, April Erwin, Simon Faissner, Ralf Gold, Joshua Katz, Mark Leekoff   +7 more
doaj   +1 more source

Multiple sclerosis susceptibility alleles in African Americans. [PDF]

, 2010
Multiple sclerosis (MS) is an autoimmune demyelinating disease characterized by complex genetics and multifaceted gene-environment interactions. Compared to whites, African Americans have a lower risk for developing MS, but African Americans with MS have
Caillier, SJ, Cree, BCA, Cross, AH, De Jager, PL, Gourraud, P-AF, Hauser, SL, Herbert, J, Johnson, BA, Khan, OA, Oksenberg, JR, Taylor, EM, Wang, J   +11 more
core  

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source

Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Corticospinal tract damage is common in people with MS, but the degree of clinical symptoms varies. We hypothesize that corticospinal tract lesions are more extensive and severe in people with MS with motor impairments in both upper and lower limbs.
Mathilde Liffran, Malo Gaubert, Alice Dufey, Elise Bannier, Audrey Rico, Jean‐Christophe Ferré, Raphaël Chouteau, Laure Michel, Emmanuelle Le Page, Virginie Callot, Bertrand Audoin, Sarah Demortière, Benoît Combès, Anne Kerbrat   +13 more
wiley   +1 more source

Microbiomes and Pediatric onset multiple sclerosis (MS): A systematic review. [PDF]

AIMS Neurosci, 2023
Mehrabani S, Rastkar M, Ebrahimi N, Ghajarzadeh M.   +3 more
europepmc   +1 more source